Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Catalent Inc
(NY:
CTLT
)
60.29
+0.20 (+0.33%)
Official Closing Price
Updated: 7:00 PM EDT, Oct 18, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Catalent Inc
< Previous
1
2
3
4
5
Next >
Catalent Publishes Fourth Annual Corporate Responsibility Report Highlighting Achievements While Providing New Record Number of Patient Treatments
February 28, 2023
From
Catalent, Inc.
Via
Business Wire
CATALENT SHAREHOLDER ALERT by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Reminds Investors With Losses in Excess Of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Catalent, Inc. - CTLT
February 27, 2023
From
Kahn Swick & Foti, LLC
Via
Business Wire
EQUITY ALERT: ROSEN, A TOP RANKED LAW FIRM, Encourages Catalent, Inc. Investors With Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – CTLT
February 27, 2023
From
The Rosen Law Firm, P.A.
Via
Business Wire
INVESTOR DEADLINE: Catalent, Inc. Investors with Substantial Losses Have Opportunity to Lead the Catalent Class Action Lawsuit – CTLT
February 27, 2023
From
Robbins Geller Rudman & Dowd LLP
Via
Business Wire
The Law Offices of Frank R. Cruz Announces Investigation of Catalent, Inc. (CTLT) on Behalf of Investors
February 27, 2023
From
The Law Offices of Frank R. Cruz
Via
Business Wire
SHAREHOLDER ACTION REMINDER: The Schall Law Firm Encourages Investors in Catalent, Inc. with Losses of $100,000 to Contact the Firm
February 27, 2023
From
The Schall Law Firm
Via
Business Wire
Shareholder Alert: Robbins LLP Informs Investors of Class Action Against Catalent, Inc. (CTLT)
February 25, 2023
From
Robbins LLP
Via
Business Wire
SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Catalent, Inc. with Losses of $100,000 to Contact the Firm
February 24, 2023
From
The Schall Law Firm
Via
Business Wire
Labaton Sucharow LLP Announces Securities Class Action Lawsuit Filed Against Catalent, Inc. and Certain Executives
February 24, 2023
From
Labaton Sucharow LLP
Via
Business Wire
The Large Cap Rally Is Largely About These 3 Stocks
February 15, 2023
With a combined weighting of more than 4%, it’s strength in these three tickers that have much to do with the S&P’s 2023 performance.
Via
MarketBeat
Topics
Economy
Stocks
Exposures
Economy
US Equities
Catalent Appoints Joseph A. Ferraro as Senior Vice President, General Counsel, Chief Compliance Officer, and Secretary
February 13, 2023
From
Catalent, Inc.
Via
Business Wire
Catalent, Inc. Reports Second Quarter Fiscal 2023 Results
February 07, 2023
From
Catalent, Inc.
Via
Business Wire
Catalent, Inc. Announces Second Quarter Fiscal Year 2023 Earnings Conference Webcast
January 20, 2023
From
Catalent, Inc.
Via
Business Wire
Catalent Appoints Ricardo Zayas as North American Biologics Operations Leader
January 17, 2023
From
Catalent, Inc.
Via
Business Wire
Sarepta and Catalent Expand Strategic Manufacturing Partnership With Commercial Supply Agreement for Duchenne Muscular Dystrophy Gene Therapy Candidate
January 05, 2023
From
Catalent, Inc.
Via
Business Wire
Catalent, Inc. to Present at the 41st Annual J.P. Morgan Healthcare Conference
January 03, 2023
From
Catalent, Inc.
Via
Business Wire
Catalent Announces Changes to its Board of Directors
December 19, 2022
From
Catalent, Inc.
Via
Business Wire
After a $100 Haircut, is Catalent an Oversold Pharma Play?
November 14, 2022
With the macro backdrop weakening for Catalent’s pharmaceutical and biotech customers, fundamental concerns could outweigh what the charts suggest.
Via
MarketBeat
Catalent, Inc. to Present at the Stephens Annual Investment Conference
November 08, 2022
From
Catalent, Inc.
Via
Business Wire
Exelixis and Catalent Enter into New License Agreement for Three Antibody-Drug Conjugate Programs with the Potential to Accelerate Exelixis’ Biologics Pipeline
November 03, 2022
From
Exelixis, Inc.
Via
Business Wire
Catalent, Inc. Reports First Quarter Fiscal 2023 Results
November 01, 2022
From
Catalent, Inc.
Via
Business Wire
Catalent, Inc. Announces First Quarter Fiscal Year 2023 Earnings Conference Webcast
October 17, 2022
From
Catalent, Inc.
Via
Business Wire
Catalent, Inc. to Present at September Investor Conferences
September 08, 2022
From
Catalent, Inc.
Via
Business Wire
Catalent, Inc. Reports Fourth Quarter Fiscal 2022 Results
August 29, 2022
From
Catalent, Inc.
Via
Business Wire
Catalent to Acquire Metrics Contract Services for $475 Million to Expand High-Potent Capabilities and Oral Development and Manufacturing Capacity
August 09, 2022
From
Catalent, Inc.
Via
Business Wire
Catalent, Inc. Announces Fourth Quarter Fiscal Year 2022 Earnings Conference Webcast
August 05, 2022
From
Catalent, Inc.
Via
Business Wire
Catalent Announces New Operating Structure
July 05, 2022
From
Catalent, Inc
Via
Business Wire
Catalent, Inc. to Present at June Investor Conferences
May 27, 2022
From
Catalent, Inc.
Via
Business Wire
Catalent, Inc. Reports Third Quarter Fiscal 2022 Results
May 03, 2022
From
Catalent, Inc.
Via
Business Wire
Catalent, Inc. Announces Third Quarter Fiscal Year 2022 Earnings Conference Webcast
April 15, 2022
From
Catalent, Inc.
Via
Business Wire
< Previous
1
2
3
4
5
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.